Richard Daniell compensation by year
TEVA PHARMACEUTICAL INDUSTRIES Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $772,754 | $836,753 |
| Bonus | $0 | $0 |
| Stock awards | $3,499,986 | $3,299,990 |
| Option awards | $0 | $0 |
| Non-equity incentive | $743,372 | $1,134,888 |
| Pension and deferred compensation | $0 | $0 |
| All other | $148,051 | $161,661 |
| Total | $5,164,163 | $5,433,292 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD DEF 14A filed April 9, 2025, accession 0001193125-25-076829, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TEVA PHARMACEUTICAL INDUSTRIES LTD filed document, accession 0001193125-25-076829. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 186,753 | $4,116,036 | — |
| PSU | 183,169 | $4,037,045 | — |
| PSU | 110,668 | $2,439,123 | — |
| RSU | 81,845 | $1,803,864 | — |
| RSU | 67,024 | $1,477,209 | — |
| PSU | 40,923 | $901,943 | — |
| RSU | 22,576 | $497,575 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
30 Form 4 lines since the FY2024 proxy (filed April 9, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-11 | Exercise or conversion | — | 20,003 | $34.70 | 75,758 |
| 2026-11-11 | Exercise or conversion derivative | — | 20,003 | $0.00 | 0 |
| 2026-11-11 | Sale | — | 20,003 | $42.80 | 55,755 |
| 2026-11-09 | Exercise or conversion derivative | — | 25,000 | $0.00 | 20,003 |
| 2026-11-09 | Sale | — | 25,000 | $42.91 | 55,755 |
| 2026-11-09 | Exercise or conversion | — | 25,000 | $34.70 | 80,755 |
| 2026-05-05 | Sale | — | 30,000 | $35.40 | 55,755 |
| 2026-03-05 | Exercise or conversion derivative | 10b5-1 | 17,295 | $0.00 | 51,887 |
The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
TEVA PHARMACEUTICAL INDUSTRIES’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Richard Francis | President and Chief Executive Officer | $15,518,947 |
| Eli Kalif | Executive Vice President, Chief Financial Officer | $6,175,059 |
| Eric Hughes | Executive Vice President, Global R&D and Chief Medical Officer | $5,754,787 |
| Richard Daniell · this page | Executive Vice President, European Commercial | $5,433,292 |
| Christine Fox | Executive Vice President, US Commercial | $5,218,023 |
The full TEVA PHARMACEUTICAL INDUSTRIES compensation record
free company briefThis page is one person within TEVA PHARMACEUTICAL INDUSTRIES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the TEVA PHARMACEUTICAL INDUSTRIES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TEVA PHARMACEUTICAL INDUSTRIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.